Cargando…

New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology

Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellasi, Antonio, Cozzolino, Mario, Malberti, Fabio, Cancarini, Giovanni, Esposito, Ciro, Guastoni, Carlo Maria, Ondei, Patrizia, Pontoriero, Giuseppe, Teatini, Ugo, Vezzoli, Giuseppe, Pasquali, Marzia, Messa, Piergiorgio, Locatelli, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Position papers and Guidelines
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118036/ https://www.ncbi.nlm.nih.gov/pubmed/31853791 http://dx.doi.org/10.1007/s40620-019-00677-0

Ejemplares similares

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
por: Cozzolino, Mario, et al.
Publicado: (2017)

Which Vitamin D in CKD-MBD? The Time of Burning Questions
por: Galassi, Andrea, et al.
Publicado: (2013)

Prevention and Treatment of CKD-MBD
por: Cozzolino, Mario
Publicado: (2013)

Nutritional treatment of advanced CKD: twenty consensus statements
por: Cupisti, Adamasco, et al.
Publicado: (2018)

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
por: Eidman, Keith E, et al.
Publicado: (2018)

SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)
por: Orlacchio, Antonio, et al.
Publicado: (2022)

CKD-MBD KDIGO guidelines: how difficult is reaching the ‘target’?
por: Cozzolino, Mario
Publicado: (2018)

Green nephrology and eco-dialysis: a position statement by the Italian Society of Nephrology
por: Piccoli, Giorgina Barbara, et al.
Publicado: (2020)

Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”
por: Russo, Domenico, et al.
Publicado: (2019)

The Role of Vitamin K in CKD-MBD
por: Fusaro, Maria, et al.
Publicado: (2022)

Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Cunningham, John, et al.
Publicado: (2019)

CKD-MBD after kidney transplantation
por: Wesseling-Perry, Katherine, et al.
Publicado: (2011)

A Japanese approach for CKD-MBD
por: Yokoyama, Keitaro, et al.
Publicado: (2013)

CKD-MBD diagnosis: biochemical abnormalities
por: Lucca, Leandro Junior, et al.
Publicado: (2021)

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism
por: Block, Geoffrey A., et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology
por: Bianchi, Stefano, et al.
Publicado: (2019)

Focus on the Possible Role of Dietary Sodium, Potassium, Phosphate, Magnesium, and Calcium on CKD Progression
por: Mazzaferro, Sandro, et al.
Publicado: (2021)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report
por: Panuccio, Vincenzo Antonio, et al.
Publicado: (2023)

Association between CKD-MBD and mortality in older patients with advanced CKD—results from the EQUAL study
por: Magagnoli, Lorenza, et al.
Publicado: (2023)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2019)

Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
por: Arenas, Maria Dolores, et al.
Publicado: (2020)

Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore
por: Khan, Behram A, et al.
Publicado: (2023)

Contraception in chronic kidney disease: a best practice position statement by the Kidney and Pregnancy Group of the Italian Society of Nephrology
por: Attini, Rossella, et al.
Publicado: (2020)

Clinical significance of parathyroid intervention on CKD-MBD management
por: Ogata, Hiroaki, et al.
Publicado: (2008)

Native Hypovitaminosis D in CKD Patients: From Experimental Evidence to Clinical Practice
por: Alfieri, Carlo, et al.
Publicado: (2019)

Epidemiology of CKD Regression in Patients under Nephrology Care
por: Borrelli, Silvio, et al.
Publicado: (2015)

What should European nephrology do with the new CKD-EPI equation?
por: Gansevoort, Ron T, et al.
Publicado: (2022)

Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin. Med. 2019, 8, 1066
por: Russo, Domenico, et al.
Publicado: (2020)

Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study
por: Filipozzi, Pierre, et al.
Publicado: (2017)

Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy
por: Friedl, Claudia, et al.
Publicado: (2018)

A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial)
por: Itano, Yuya, et al.
Publicado: (2020)

A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride
por: Nakamura, Hironori, et al.
Publicado: (2021)

A best-practice position statement on pregnancy after kidney transplantation: focusing on the unsolved questions. The Kidney and Pregnancy Study Group of the Italian Society of Nephrology
por: Cabiddu, Gianfranca, et al.
Publicado: (2018)

Gaps between Global Guidelines and Local Practices in CKD-MBD
por: Kim, Gheun-Ho
Publicado: (2014)

CKD-MBD in Brazil: the gap between reality and the recommended guidelines
por: Custódio, Melani Ribeiro
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i21s4q2ljmev2rvf71rbcm3cdt